Sickle cell disease (SCD) may present a stable clinical condition with the advancement of pharmacological treatment and available technologies for early diagnosis. 1 However, if not diagnosed and treated early, it may lead to progressive organ damage and even fatal complications. 2 Therefore, it is important to develop different instruments to assess the SCD prognosis. The maximal treadmill test (MTT), widely used in different diseases, such as heart failure, can play an important role in the risk stratification of these patients, since they usually have chest pain associated with vessel occlusion, causing myocardial ischemia and, consequently, sudden death, something very common in these individuals. 3,4